Figure 3

Mutation accounts for the majority of genetic aberration in JMJD3. (A) The percentage of JMJD3 genetic alteration in different GC patient cohorts analyzed by cBioportal. (B) The position of JMJD3 mutation in the four patient cohorts combined together cohorts analyzed by cBioportal. (C) Representative percentage of different genetic alteration in JMJD3 and the accompanying expression change cohorts analyzed by cBioportal. (D) Representative diagram of the two pMSCV plasmids established for functional study. (E) MTT result after transfection of wildtype or mutant JMJD3 plasmids in two GC cell lines. (F) MTT result after transfection of JMJD3 plasmids with or without GSK-J4. (G) BrdU result after transfection of JMJD3 plasmids with or without GSK-J4. *p < 0.05, **p < 0.01 and ***p < 0.001.